On target: With the fully synthetic vaccine 1 consisting of a tumor-associated sialyl-Tn glycopeptide antigen from the epithelial mucin MUC1 and a T-cell epitope from ovalbumin, a strong, highly specific immune response (IgG) directed against the glycopeptide antigen was induced in a mouse thereby realizing the most important requirement for the development of synthetic vaccines for the initiation of the body's own immune defense against tumors.
No takes yet. Share an insight, caveat, or question.
Dziadek et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: